Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024
- Revenue increased by 21% to $2.97 million compared to Q3 FY23
- Gross margin improved to 73% from 57% YOY
- Net loss decreased by 36% YOY to $3.0 million
- Focus on long-term growth, operational efficiency, and developing innovative solutions like the Cardiac AI Cloud Platform
- None.
Insights
The reported increase in recurring subscription revenue by 23% YOY for Biotricity Inc. is a significant indicator of the company's transition towards a more stable and predictable revenue model. This shift from variable to fixed revenue streams is particularly favorable as it reduces the impact of seasonality and enhances the company's ability to forecast future earnings. Furthermore, the improvement in gross margins to 73% reflects effective cost management and operational efficiencies, likely driven by the integration of proprietary AI technology. The reported net loss decrease of 36% year-over-year suggests a stronger financial position and a potential reduction in future capital needs.
However, while the reduction in net loss is an encouraging sign, the company still operates at a loss, which indicates ongoing challenges in achieving profitability. Investors should consider the company's long-term strategy and the scalability of its TaaS model in the context of the broader healthcare technology sector. The expansion of the geographic footprint and product portfolio, catering to a $35 billion total addressable market, could be pivotal for growth, but it also necessitates substantial market penetration to capitalize on this opportunity.
Biotricity's strategic focus on the remote cardiac monitor sector taps into the growing demand for telehealth and remote patient monitoring solutions. Their emphasis on customer retention and cardiologist-friendly support services underscores the importance of user experience in healthcare technology adoption. The development of the Cardiac AI Cloud Platform represents an innovation trajectory that could differentiate Biotricity in a competitive market. Predictive monitoring capabilities align with industry trends towards preventative healthcare measures and could contribute to reducing overall healthcare costs by minimizing readmissions.
Expansion to 35 states indicates an aggressive growth strategy, but it's essential to scrutinize the scalability of their operations and the effectiveness of their sales force restructuring. The emphasis on larger accounts and independent hospitals could lead to significant contracts, but longer sales cycles might affect short-term cash flow. The company's ability to continue growing its subscription base while managing the sales process efficiently will be critical for its success.
The upward trend in gross margins can be partially attributed to Biotricity's operational automation, which likely involves advanced data analytics and machine learning algorithms to optimize monitoring costs. This technological edge is not only a catalyst for margin improvement but also enhances the company's value proposition in terms of the accuracy and reliability of diagnostics. The cardiac remote patient monitoring devices market is becoming increasingly sophisticated and Biotricity's investment in its Cardiac AI Cloud Platform could be a game-changer in predictive healthcare.
It's important to note the potential impact of such technologies on the healthcare system. If Biotricity's solutions can indeed lower readmission rates, this could result in significant cost savings for healthcare providers and insurers. Moreover, the ability to detect cardiac issues before they arise could improve patient outcomes significantly. The long-term implications for stakeholders, including patients, healthcare providers and payers, could be substantial, provided that the technology is adopted at scale and demonstrates clinical efficacy.
- Topline growth with better quality revenue mix
- Increase in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenue
- Improved margins
- Lower costs with improved selling expense
- Stronger path to breakeven
REDWOOD CITY, CA / ACCESSWIRE / February 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the third quarter of fiscal 2024 year and (unaudited) ended December 31, 2023.
Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter was marked by record margins, lowered costs and increasing revenues, supporting our path towards positive cashflow. The major theme for us was on long-term building- which meant reshaping our sales force to focus on efficiencies, longer sales cycles, larger accounts and independent hospitals and Group Purchasing Organizations- the necessary steps towards establishing recurring technology subscriptions and long-term growth.
We continue to leverage our data intelligently, pushing the boundaries of operational automation and efficiency, and in January of 2024, we announced the development of our Cardiac AI Cloud Platform. This platform is being designed for predictive monitoring, helping physicians and users in detecting potential issues before they arise. This supports our objective for early interventions, which decreases the likelihood of readmissions, and contributes to lowering healthcare costs. Biotricity's product portfolio is already recognized as one of the most extensive remote cardiac monitoring collections worldwide, and this further reinforces our commitment to advanced healthcare solutions.
Our gross margins continue to trend upward, and we have successfully managed expenses, all while penetrating the market and securing market leadership in cardiac remote patient monitoring devices and solutions."
Q3-FY24 Financial Highlights
- Revenue increased
21% to$2.97 million compared with$2.46 million in Q3 FY23 - Gross margin was
73% for the three months ended December 31, 2023, as compared to57% in the corresponding prior year quarter, as a result of expansion in recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring cost structure. - Net loss decreased
36% YOY to$3.0 million , or$0.34 per share, from a net loss of$4.7 million , or$0.55 per share, in Q3-FY23
Operating Highlights for Q3-FY24
- Q3-FY24 recurring (TaaS) Technology Fees rose a robust
23% YOY to$2.78 million , representing over 14 times Device Sales revenue - Company maintained its track record of strong customer retention that is supported by the quality of customer and cardiologist-friendly support services that emphasize accuracy of diagnostics and ease-of-use.
- Developed a range of state-of-the-art products to service a total addressable market of
$35 billion . - Expansion of geographic footprint to 35 states, with thousands of cardiologists over hundreds of centers.
- Continued trend to reach positive cash flow by growing subscription-based revenues, improving margins, and leveraging automation and experience to increase efficiencies of SG&A.
Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting www.sec.gov.
Financial Results and Business Update Conference Call
Management will host a conference call on Wednesday, February 21, 2024 at 4:30 p.m. ET to discuss its financial results for the fiscal 2024 third quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/
Event: Biotricity Third Quarter FY 2024 Financial Results and Business Update Call
Date: Wednesday, February 21st
Time: 4:30pm ET (1:30pm PT)
Toll Free: 877-497-9071
International: +1 201-689-8727
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=W6rURVEu
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 877-660-6853
International: 201-612-7415
Replay Access ID: 13744622
Expiration: March 6, 2024, 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
View the original press release on accesswire.com
FAQ
What is the revenue growth percentage for Biotricity Inc. in Q3 FY24?
What is the gross margin percentage for Biotricity Inc. in Q3 FY24?
How much did the net loss decrease by in Q3 FY24 for Biotricity Inc.?
What innovative platform did Biotricity Inc. announce in January 2024?
What is the focus of Biotricity Inc. for long-term growth?
